GENSIGNIATM MSC LUNG CANCER TEST
GENSIGNIA’s MSC (“microRNA Signature Classifier”) Lung Cancer Test in development addresses the most common cancer in the world, which affects an estimated 2 million people. It is a plasma-based test aimed at decreasing the high rate of false positives from low-dose (spiral) computed tomography (LDCT).
The current standard-of-care diagnostic has a very high error rate. Heavy smokers are recommended to undergo low-dose spiral CT (LDCT) scans annually. A landmark study showed that about 25% of patients that undergo LDCT are thought to have lung cancer, however, more than 96% of those positive scans are “false positives” which result in additional testing that is costly and potentially harmful to patients. GENSIGNIA’s test may be used to confirm LDCT scans, reducing the need for additional diagnostic work ups.
The Burden of Lung Cancer
Lung cancer is the leading cause of cancer death and the second most diagnosed cancer in both men and women in the United States. Because lung cancer is usually detected in its later stages, more than 80% of patients die within 2 years of diagnosis. Early detection therefore extends life and offers patients a chance to be cured. GENSIGNIA’s test is designed to help physicians accurately diagnose this form of cancer, and catch it in earlier stages.
READ MORE >